top of page
Vaccine Production Line
Latest Developments in Medical Drugs Lawsuits

Legal Cases Involving Pharmaceuticals

The legal landscape for pharmaceutical companies continues to evolve with several high-profile cases making headlines in 2024. Here are some of the most significant recent developments in medical drug lawsuits:

Ozempic and Mounjaro Lawsuits

Ozempic (semaglutide) and Mounjaro (tirzepatide), both diabetes and weight-loss drugs, are at the center of extensive litigation. Plaintiffs allege that these medications caused severe gastrointestinal issues such as gastroparesis and ileus, which were not adequately disclosed by the manufacturers, Novo Nordisk and Eli Lilly. As of February 2024, at least 55 lawsuits have been consolidated into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. The litigation process has faced delays due to the unexpected death of the presiding judge, but proceedings are expected to move forward under the new oversight of Judge Karen S. Marston​​.

Zantac Settlements

Zantac (ranitidine), a popular heartburn medication, was pulled from the market in 2019 after it was found to contain N-nitrosodimethylamine (NDMA), a probable carcinogen. In May 2024, Pfizer agreed to settle 10,000 lawsuits for up to $250 million. These lawsuits claim that long-term use of Zantac led to various cancers, and the settlements mark a significant step towards resolving the vast litigation landscape surrounding this drug. This follows similar settlements by other manufacturers like Sanofi​.

Philips CPAP Lawsuits

Philips Respironics reached a $1.1 billion settlement in April 2024 over lawsuits related to its CPAP machines. These devices were recalled due to potential health risks from foam degradation, which could cause respiratory issues or cancer. This settlement covers personal injury claims and provides for medical monitoring of affected users​​.

Paraquat Herbicide Lawsuits

Although not a pharmaceutical, the toxic tort cases surrounding the herbicide Paraquat have significant overlap with medical drug litigation due to their health impacts. Nearly 5,000 cases are pending, alleging that long-term exposure to Paraquat causes Parkinson’s disease. The consolidation of these cases into MDL highlights the growing concern over chemical exposure and its health consequences​​.

Conclusion

The surge in pharmaceutical and toxic tort litigation underscores the critical need for transparency and rigorous safety standards in the production and marketing of medical drugs. For those affected by these drugs, understanding the legal landscape and seeking experienced legal counsel can be vital steps towards securing compensation and holding manufacturers accountable.

For more detailed information or to schedule a consultation, please contact us here.

bottom of page